₹0.97
▼ -0.02 -2.02%
28 Oct 2026
BSE Listed
Genpharmasec Limited (531592)
Volume: 2,28,380Avg Vol 1W: 3,00,019Avg Vol 1M: 3,69,86052W Range:₹0.75₹1.8
Key Ratios
Checked 1h agoMarket Cap₹54 Cr
Current Price₹0.97
Previous Close₹0.99
High / Low (52w)₹1.8 / ₹0.75
Volume2,28,380
Avg Vol (1W)3,00,019
Avg Vol (1M)3,69,860
Stock P/E34.33
Book Value₹1.2
Dividend Yield0%
ROE241.95%
ROA-60.08%
Revenue (TTM)—
Revenue Growth—
Profit Margin-14.64%
Total Debt—
Shares Outstanding55 Cr
Face Value—
EPS (TTM)₹0
P/B0.81
Debt / Equity0.31
50 DMA₹1.08
200 DMA₹1.13
Day change-2.02%
Price Chart
₹0.97▼ 45.20% · 1Y
2025-10-282026-10-28
20-day avg volume: 3.8L shares
Pros
- Healthy return on equity of 241.9%.
- Company is almost debt-free.
- Stock trades below its book value.
Cons
- Revenue fell 69% YoY.
Quarterly Results
| Metric | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹6 Cr | ₹8 Cr | ₹14 Cr | ₹12 Cr | ₹33 Cr | ₹40 Cr | ₹55 Cr | ₹50 Cr |
| EBITDA | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹-1 Cr | ₹-1 Cr | ₹2 Cr | ₹1 Cr |
| Net Profit | ₹1 Cr | ₹1 Cr | ₹0 Cr | ₹1 Cr | ₹-1 Cr | ₹-1 Cr | ₹1 Cr | ₹0 Cr |
| EPS | — | — | — | — | — | — | — | — |
Profit & Loss (Annual)
| Metric | Mar 2025 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹14 Cr | ₹37 Cr | ₹12 Cr | ₹32 Cr | ₹36 Cr | ₹143 Cr | ₹52 Cr | ₹45 Cr |
| EBITDA | ₹0 Cr | ₹3 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹3 Cr | ₹2 Cr |
| Net Profit | ₹0 Cr | ₹2 Cr | ₹2 Cr | ₹1 Cr | ₹1 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
| EPS | — | 0.03 | — | — | — | 0.01 | — | — |
Balance Sheet
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | ₹20 Cr | ₹71 Cr | ₹80 Cr | ₹138 Cr |
| Total Liabilities | ₹5 Cr | ₹7 Cr | ₹15 Cr | ₹73 Cr |
| Equity | ₹15 Cr | ₹65 Cr | ₹65 Cr | ₹66 Cr |
| Total Debt | — | — | — | — |
Cash Flow
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating | ₹-3 Cr | ₹-3 Cr | ₹3 Cr | ₹-17 Cr |
| Investing | ₹0 Cr | ₹-28 Cr | ₹-4 Cr | ₹13 Cr |
| Financing | ₹3 Cr | ₹48 Cr | ₹-1 Cr | ₹4 Cr |
| Free Cash Flow | ₹-3 Cr | ₹-3 Cr | ₹3 Cr | ₹-17 Cr |
Shareholding
Promoter 32.06% Institutions 0% Public 67.94%
Efficiency & Working Capital
ROCE2.2%
Interest Coverage1.8
Dividend Payout—
Debtor Days76 d
Inventory Days36 d
Payable Days82 d
Cash Conversion Cycle30 d
Working Capital Days113 d
Shareholding Details
As of 2026-09-30
Promoter32.1%
FII0%
DII0%
Institutions0%
Public67.9%
Promoter Pledge0%
No. of Shareholders99,856
Shareholding Pattern
Quarterly — figures in %. Latest 12 quarters.
| Period | Feb 2024 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sept 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 30% | 32.1% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 70% | 67.9% |
| Promoter Pledge | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| No. of Shareholders | 1,05,693 | 1,08,137 | 1,08,220 | 1,05,838 | 1,09,206 | 1,09,080 | 1,07,602 | 1,05,804 | 1,04,021 | 1,02,252 | 1,01,134 | 99,856 |
Returns History (ROE / ROCE / ROA)
| Period | ROE | ROCE | ROA | P/E |
|---|---|---|---|---|
| 202603 | — | — | — | — |
Major Shareholders (>1%)
| Name | Category | Stake | Shares |
|---|---|---|---|
| Sneha Sadhwani | Shareholding of Promoter and Promoter Group | 16.8% | 9.30 Cr |
| Rajesh Sadhwani | Shareholding of Promoter and Promoter Group | 15.3% | 8.45 Cr |
| Rushabh Sevantilal Sanghavi | Public Shareholding | 3.4% | 1.89 Cr |
| Sadashiv Kanyana Shetty | Public Shareholding | 2.1% | 1.14 Cr |
| Vishesh Mahesh Nihalani | Public Shareholding | 1.5% | 84,00,100 |
| L7 Hitech Private Limited | Public Shareholding | 1.2% | 68,84,159 |
| Narendra Chhaganlal Solanki | Public Shareholding | 1.1% | 60,09,409 |
| Nimesh Shambhulal Joshi | Public Shareholding | 1% | 55,68,556 |
Board of Directors
| Name | Designation | Year |
|---|---|---|
| Mr. Sohan Chaturvedi | Executive Director / Whole Time Director / CFO | 2025 |
| Rajesh Sadhwani | Non-Exec & Non-Independent Dir | 2025 |
| Sneha Sadhwani | Non-Exec & Non-Independent Dir | 2025 |
| Siddhesh Shankar Shende | Independent Non Exe. Director | 2025 |
| Mayur Bharatbhai Bhatt | Independent Non Exe. Director | 2025 |
| Sachin Aphandkar | Independent Non Exe. Director | 2025 |
| Hardik Makwana | Company Sec. & Compli. Officer | 2025 |
Segments — Product
| Segment | Revenue | Share |
|---|---|---|
| Diagnostic Pharma Equipment | ₹33 Cr | 100% |
| Trading in Securities | ₹0 Cr | 0% |
Capital Structure (₹ Cr)
| Year | Face Value | Authorised | Issued | Paid-up |
|---|---|---|---|---|
| 2026 | ₹1 | 56 | 55 | 55 |
Corporate Actions
| Type | Date | Value | Remark |
|---|---|---|---|
| forthcoming | 2026-08-11 | Board Meetings | — |
Related-Party Transactions (₹ Cr)
| Year | Subsidiaries | Associates | JV | KMP | Others | Total |
|---|---|---|---|---|---|---|
| 2026 | 34 | 0 | 0 | 6 | 0 | 40 |
| 2026 | 2 | 0 | 0 | 1 | 0 | 3 |
| 2026 | 30 | 0 | 0 | 5 | 0 | 34 |
Insider / Designated-Person Trades
2 recent disclosure(s)
Rajesh SadhwaniAcquisition · 65,00,000
Rajesh SadhwaniAcquisition · 50,00,000
Substantial Acquisitions (SAST)
1 disclosure(s)
Rights Issue22/02/2024 · 4,60,00,000
Company Information
Incorporated1992
AuditorAbhishek S Tiwari & Associates
Investor Email[email protected]; [email protected]
📍 Office 104 & 105 1st Flr, Gundecha Indl Kandivali (East), Mumbai, Maharashtra, 400101
Technical AnalysisPremium
Technical analysis (Premium)
Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.
More stocks
Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search
